ERBB2 and breast carcinoma: Additionally, we noted the downregulation of SCD, coupled with the upregulation of PTGS1 and PTGSE, in tumor samples from some HER2‐positive breast cancer patients exhibiting secondary trastuzumab resistance compared to trastuzumab‐sensitive patients.